• DOI:10.1038/nrd.2015.35
Corpus ID: 54550859

Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations

@article{Hoos2016DevelopmentOI,
  title={Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations},
  author={A. Hoos},
  journal={Nature Reviews Drug Discovery},
  year={2016},
  volume={15},
  pages={235-247}
}

A. Hoos

Published 2016

Medicine

Nature Reviews Drug Discovery

Since the regulatory approval of ipilimumab in 2011, the field of cancer immunotherapy has been experiencing a renaissance. This success is based on progress in both preclinical and clinical science, including the development of new methods of investigation. Immuno-oncology has become a sub-specialty within oncology owing to its unique science and its potential for substantial and long-term clinical benefit. Immunotherapy agents do not directly attack the tumour but instead mobilize the immune… CONTINUE READING

View on Nature

nature.com

Save to Library

Create Alert

Cite

Launch Research Feed